Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference

Myriad Genetics (NASDAQ: MYGN) announced that Sam Raha, president and CEO, will present at the 44th Annual J.P.

Rhea-AI Summary

Myriad Genetics (NASDAQ: MYGN) announced that Sam Raha, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026 at 5:15 pm PT (8:15 pm ET). The presentation will be available via a live webcast and an archived replay at the company’s investor website: investor.myriad.com.

Argus Jan 6 session

+6.19% close to close Open Argus

Details

News Market Reaction – MYGN

On Jan 6, the first trading day after this news, MYGN closed 6.19% above the previous close.

Data tracked by StockTitan Argus for the Jan 6 session.

Market Context

On Jan 6, the first trading day after this news, the stock closed 6.2% above the previous close. A s...

Analysis

On Jan 6, the first trading day after this news, the stock closed 6.2% above the previous close. A strong positive reaction aligns with Myriad’s pattern of investor interest around major conferences and data showcases, as seen after prior SABCS and investor conference announcements with moves of up to 3–4%. However, past divergence on other upbeat news suggests conference exposure alone has not guaranteed sustained strength. Investors have also navigated ongoing operating losses and leadership changes, which could temper enthusiasm once initial conference-related momentum fades.

Key Figures

Conference edition: 44th Annual Presentation date: Jan. 14, 2026 Presentation time PT: 5:15 pm PT +1 more

Conference edition

44th Annual

J.P. Morgan Healthcare Conference

Presentation date

Jan. 14, 2026

Scheduled conference presentation in San Francisco

Presentation time PT

5:15 pm PT

Scheduled time for J.P. Morgan presentation

Presentation time ET

8:15 pm ET

Simulcast time for J.P. Morgan presentation

Historical Context

5 past events · Latest: Dec 09

5 events

1. Dec 09

   Conference research data

   24h Move

   +4.0%

   Presentation of 8 SABCS abstracts including MRD and expanded MyRisk data.

2. Nov 25

   Product collaboration

   24h Move

   -3.9%

   Launch of integrated AI and genetic breast health risk platform with partners.

3. Nov 11

   Investor conferences

   24h Move

   +3.1%

   Planned participation in Wolfe and Piper Sandler healthcare investor conferences.

4. Nov 10

   Product expansion

   24h Move

   +2.9%

   Added 15 genes to MyRisk, expanding to 63 guideline-aligned hereditary cancer genes.

5. Nov 06

   Conference research data

   24h Move

   -3.8%

   Planned 11 new studies at NSGC conference on oncology and reproductive testing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

molecular diagnostic testing, precision medicine, webcast

3 terms

molecular diagnostic testing medical

"Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine"

Molecular diagnostic testing uses tools that read the genetic material or specific molecules from a tissue, blood, or swab sample to detect disease, identify pathogens, or predict how a patient will respond to treatment. Think of it like a highly detailed fingerprint check for the biology of an illness. Investors care because these tests drive sales, regulatory scrutiny, and reimbursement decisions, so accuracy, adoption, and approval directly affect a company’s revenue and growth prospects.

precision medicine medical

"a leader in molecular diagnostic testing and precision medicine, today announced that Sam Raha"

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

webcast technical

"The presentation will be available through a live webcast and archived at investor.myriad.com."

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Sam Raha, president and CEO, will present at the 44^th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, at 5:15 pm PT (8:15 pm ET).

The presentation will be available through a live webcast and archived at investor.myriad.com. 

About Myriad Genetics  
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com. 

Investor Contact  
Matt Scalo  
(801) 584-3532  
IR@myriad.com  

Media Contact  
Kate Schraml 
(224) 875-4493 
PR@myriad.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Myriad Genetics (MYGN) present at the J.P. Morgan Healthcare Conference?

Myriad Genetics will present on Wednesday, Jan. 14, 2026 at 5:15 pm PT (8:15 pm ET).

Who from Myriad Genetics will present at the Jan. 14, 2026 conference?

Sam Raha, president and CEO of Myriad Genetics, will deliver the presentation.

How can investors watch Myriad Genetics (MYGN) presentation on Jan. 14, 2026?

The presentation will be available via a live webcast and an archived replay at investor.myriad.com.

What time is Myriad Genetics (MYGN) presenting in Eastern Time?

The presentation is scheduled for 8:15 pm ET on Jan. 14, 2026.

Will a replay of the Myriad Genetics presentation be available after Jan. 14, 2026?

Yes. An archived replay will be posted at investor.myriad.com following the live webcast.